2019
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M, Szabó A, Ugwu N, Mani MV, Azari B, Kayingo G, Chung S, Fathzadeh M, Weiss E, Bender J, Mane S, Lifton RP, Adeniran A, Nathanson MH, Gorelick FS, Hwa J, Sahin-Tóth M, Belfort-DeAguiar R, Kibbey RG, Mani A. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nature Genetics 2019, 51: 1233-1243. PMID: 31358993, PMCID: PMC6675645, DOI: 10.1038/s41588-019-0470-3.Peer-Reviewed Original ResearchConceptsEarly-onset atherosclerosisMetabolic syndromeMetabolic syndrome traitsWhole-exome sequence analysisAttractive therapeutic targetPlatelet hyperactivationInsulin levelsPlasma insulinPlasma levelsInsulin sensitivityInsulin secretionTherapeutic targetPlatelet activationDisease mechanismsSyndrome traitsAtherosclerosisFunction mutationsSyndromeNovel lossInsulinMutationsSecretion
2015
The Genetic Challenges and Opportunities in Advanced Heart Failure
Hannah-Shmouni F, Seidelmann SB, Sirrs S, Mani A, Jacoby D. The Genetic Challenges and Opportunities in Advanced Heart Failure. Canadian Journal Of Cardiology 2015, 31: 1338-1350. PMID: 26518444, PMCID: PMC5423787, DOI: 10.1016/j.cjca.2015.07.735.BooksNew targets to treat obesity and the metabolic syndrome
Martin KA, Mani MV, Mani A. New targets to treat obesity and the metabolic syndrome. European Journal Of Pharmacology 2015, 763: 64-74. PMID: 26001373, PMCID: PMC4573317, DOI: 10.1016/j.ejphar.2015.03.093.Peer-Reviewed Original ResearchConceptsMetabolic syndromeCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsPancreatic lipase inhibitor orlistatSingle CVD risk factorPeptide-1 receptor agonistsCVD risk factorsEpidemic of obesityLong-term treatmentType 2 diabetesLipase inhibitor orlistatDipeptidyl peptidase IV inhibitorsAnti-diabetic drugsFuture drug developmentTruncal obesitySerotonergic drugsReceptor agonistRisk factorsMelanocortin systemObesityMetabolic traitsSyndromeMetabolic profileIV inhibitorsNew targets